drugset
drugset / Trial / NCT03714334

DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma

NCT03714334 ↗

Phase 1 Terminated 16 enrolled Clinica Universidad de Navarra, Universidad de Navarra DNAtrix, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

Patients with first or second recurrence of GBM will be treated with stereotactic injection of the oncolytic virus DNX-2440.

Timeline

Start
2018-10-16
Primary completion
2023-04-05
Completion
2023-04-05

Outcome

Outcome not reported

Stopped: “Break of stock”

Drugs

EvaluationDrugModalityDoseRoute
Subject TEZEMLIMOGENE DAXADENOREPVEC Unknown — Other

Indications

adult glioblastoma